Company news
Shanghai Pharmaceuticals Holding Co. Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Report for Q3 2026
October 29, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Resolutions of the 6th Meeting of the 9th Board of Directors
October 29, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Renewal of the Property Leasing Framework Agreement with Shanghai Pharmaceutical (Group) Co., Ltd. and Routine Related Party Transaction/Continuing Connected Transaction
October 29, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Renewal of the Procurement Framework Agreement with Wing Fat Printing Limited and the Routine Related Party Transaction/Continuing Connected Transaction
October 29, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Renewal of Sales and Distribution Agreement with Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. and Routine Related Party Transaction
October 29, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Progress of Drug Clinical Trials
October 23, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 23, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Clevidipine Emulsion Injection
October 9, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Transfer of Equity Interests in Zeus Investment Limited and Its Affiliates
September 29, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Annual Operating Performance Assessment and Compensation Plan for Senior Executives
September 29, 2026
Announcement on Resolutions of the 5th Meeting of the 9th Board of Directors
September 29, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Isavuconazonium Sulfate for Injection
September 28, 2026
(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Esomeprazole Magnesium Enteric-coated Capsules
September 28, 2026
Announcement on Approval for Production of Paclitaxel Injection
September 28, 2026
Announcement on Implementation of Dividend Distribution for the First Half of 2026
September 10, 2026
Announcement on Approval for Production of Ruxolitinib Phosphate Tablets
August 31, 2026
Semi-annual Report for 2026
August 27, 2026
Announcement on Resolutions of the 3rd Meeting of the 9th Board of Directors
August 24, 2026
Announcement on Approval for Production of Omeprazole and Sodium Bicarbonate Dry Suspension (I)
August 3, 2026
Announcement on Obtaining Canadian Product Licenses for DRAGON & TIGER Qingliang You Regular (Cooling Ointment), DRAGON & TIGER Qingliang You Ultra (Cooling Ointment) and DRAGON & TIGER Fengyou Jing Oil (Roll-On Medicated Oil)
July 30, 2026
Announcement on Reply to the Shanghai Stock Exchange's Information Disclosure Supervisory Inquiry Letter on the Company's 2025 Annual Report
July 24, 2026
Announcement on the Receipt of Clinical Trial Approval Notice for Qingrun Yangmu Granules
July 20, 2026
Announcement on Resolutions of the 2nd Meeting of the 9th Board of Directors
July 17, 2026
Announcement on Implementation of Dividend Distribution for 2025
July 9, 2026
Correction Announcement for the Announcement on Resolutions of the 2025 Annual General Meeting
July 8, 2026
Announcement on the Completion of Implementation of Controlling Shareholder's Share Increase Plan and Results
July 1, 2026
Announcement on Obtaining Approval for Production of Vigabatrin Powder for Oral Solution
June 29, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 25, 2026
Announcement on Election of Employee Representative Director for the 9th Board of Directors
June 17, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
June 12, 2026
Notice on Convening the 2025 Annual General Meeting
June 3, 2026
Announcement on Subsidiary Becoming the Marketing Authorization Holder of Trazodone Hydrochloride Tablets
May 28, 2026
Announcement on the Interim Dividend Distribution Arrangement in 2026
May 27, 2026
Announcement on Obtainment of Drug Registration Certificate for Rivaroxaban Tablets in Thailand
May 7, 2026
Report for Q1 2026
April 29, 2026
Announcement on Progress in Proposed Public Listing and Transfer of 30% Equity in Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd.
April 28, 2026
Announcement on Prednisolone Tablets Passing Generic Drug Consistency Evaluation
April 24, 2026
Announcement on Digoxin Tablets Passing Generic Drug Consistency Evaluation
April 8, 2026
Announcement on Proposed Issuance of Debt Financing Products
March 30, 2026
Announcement on Convening the 2025 Annual Performance Briefing
March 26, 2026
Announcement on Completion of Generic Drug Consistency Evaluation for Cefazolin Sodium for Injection
March 17, 2026
Announcement on Subsidiary Obtaining Philippine Drug Registration Certificate for Pregabalin Capsules
February 27, 2026
Announcement on Obtainment of Drug Registration Certificate for Rivaroxaban Tablets in Singapore
February 24, 2026
Announcement on Independent Exercise Results of Reserved Stock Options in the 3rd Vesting Period of 2019 A-share Stock Option Incentive Plan
February 11, 2026
Announcement on Obtaining Approval for Production of Sitagliptin and Metformin Hydrochloride Sustained-release Tablets
February 4, 2026
Announcement on the Receipt of Clinical Trial Approval Notice for Qiling Granules
January 29, 2026
Announcement on Obtaining Approval for Production of Avatrombopag Maleate Tablets
January 23, 2026
Announcement on the Receipt of Clinical Trial Approval Notice for B023 Cell Injection Solution
January 20, 2026
Announcement on Completion of Acquisition of 10% Equity of SIIC Finance Co., Ltd. and Related Party Transactions
January 13, 2026
Announcement on Obtaining Approval for Production of Pyridostigmine Bromide Oral Solution
January 9, 2026
Decks
- Investor Presentation (March 2018)
Investor deck · 23 slides · Mar 26, 2018